Back
Rate this talk
Your peers have not rated this talk yet.
4-minute watch | Talk 5 of 5

EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL

Summary

Prof. Catherine Thieblemont
SYMPOSIUM
EBMT

Prof. Catherine Thieblemont
Hospital Saint-Louis, Paris, France

Prof. Catherine Thieblemont, Hospital Saint-Louis, Paris, France, summarises the key arguments and evidence gaps from the debates on the earlier use and the curative potential of CAR T-cell therapy vs. bispecific antibodies for the treatment of R/R DLBCL

Read more

Talks in this series

Prof. Max Topp, Prof Catherine Thieblemont, Dr Miguel-Angel Perales and Dr William Townsend present at EBMT (CAR T vs. BsAbs in R_R DLBCL)
1-minute watch | Talk 1 of 5
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL
Series trailer
Prof. Max Topp, Prof Catherine Thieblemont, Dr Miguel-Angel Perales and Dr William Townsend present at EBMT (CAR T vs. BsAbs in R_R DLBCL)
1-minute watch
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL

Series trailer

Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
6-minute watch | Talk 2 of 5
Welcome and introduction
Prof. Catherine Thieblemont
Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
6-minute watch

Welcome and introduction

Prof. Catherine Thieblemont

Dr William Townsend presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
24-minute watch | Talk 3 of 5
CAR T should be used as early as possible in the treatment of R/R DLBCL
Prof. Catherine Thieblemont, Dr William Townsend
Dr William Townsend presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
24-minute watch

CAR T should be used as early as possible in the treatment of R/R DLBCL

Prof. Catherine Thieblemont, Dr William Townsend

Dr Miguel-Angel Perales presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
20-minute watch | Talk 4 of 5
CAR T‑cell therapy is the most recent therapy with curative potential for the treatment of R/R DLBCL
Prof. Max Topp, Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
20-minute watch

CAR T‑cell therapy is the most recent therapy with curative potential for the treatment of R/R DLBCL

Prof. Max Topp, Dr Miguel-Angel Perales

Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
4-minute watch | Talk 5 of 5
Summary
Prof. Catherine Thieblemont
Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
4-minute watch

Summary

Prof. Catherine Thieblemont

Prof. Max Topp, Prof Catherine Thieblemont, Dr Miguel-Angel Perales and Dr William Townsend present at EBMT (CAR T vs. BsAbs in R_R DLBCL)
1-minute watch | Talk 1 of 5
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL
Series trailer
Prof. Max Topp, Prof Catherine Thieblemont, Dr Miguel-Angel Perales and Dr William Townsend present at EBMT (CAR T vs. BsAbs in R_R DLBCL)
1-minute watch
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL

Series trailer

Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
6-minute watch | Talk 2 of 5
Welcome and introduction
Prof. Catherine Thieblemont
Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
6-minute watch

Welcome and introduction

Prof. Catherine Thieblemont

Dr William Townsend presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
24-minute watch | Talk 3 of 5
CAR T should be used as early as possible in the treatment of R/R DLBCL
Prof. Catherine Thieblemont, Dr William Townsend
Dr William Townsend presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
24-minute watch

CAR T should be used as early as possible in the treatment of R/R DLBCL

Prof. Catherine Thieblemont, Dr William Townsend

Dr Miguel-Angel Perales presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
20-minute watch | Talk 4 of 5
CAR T‑cell therapy is the most recent therapy with curative potential for the treatment of R/R DLBCL
Prof. Max Topp, Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
20-minute watch

CAR T‑cell therapy is the most recent therapy with curative potential for the treatment of R/R DLBCL

Prof. Max Topp, Dr Miguel-Angel Perales

Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
4-minute watch | Talk 5 of 5
Summary
Prof. Catherine Thieblemont
Prof Catherine Thieblemont presents at EBMT (CAR T vs. BsAbs in R_R DLBCL)
4-minute watch

Summary

Prof. Catherine Thieblemont

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.